Drug Safety Testing Center Co., Ltd. has been providing high-quality non-clinical services for over 40 years. This page will walk you through the key features of their non-clinical studies, examples of disease models, and available case studies. We hope you can use this information for a reference when selecting a contract research organization (CRO).
The Center is committed to provide timely and attentive service in response to client requests. Data submission for sensitization and manual patch clamp tests is exceptionally fast. A dedicated support plan is also available for clients requesting the tests for the first time.
The Center carefully addresses questions that may arise before or after a study—such as “What evaluation items are necessary?” or “What should be the next step after unexpected results?” Based on the characteristics of the test article and client target goals, the most suitable testing solution is proposed.
The Center believes that pricing is as important as quality. Its motto is to deliver high-quality data at reasonable costs without compromising scientific standards. By continuously seeking efficiency, the Center offers cost-effective services that maintain a strong balance between quality, delivery, and price.
It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.
However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.
Below are some examples of disease models offered at Ina Research.
This rabbit model is used in ophthalmic pharmacology studies for glaucoma and retinal research. As a chronic glaucoma model capable of maintaining sustained high intraocular pressure, it is suitable for evaluating drugs targeting to lower intraocular pressure, treat glaucoma-related optic neuropathy, or address retinopathy.
This model is used as a corneal disease model in ophthalmic pharmacology studies. Dry eye conditions are reproduced by applying a controlled air flow to the canine cornea, causing corneal dryness. It is used for evaluating therapeutic agents for corneal epithelial damage and dry eye syndrome.
This rat model is also used for glaucoma and retina-related research. Retinopathy is reproduced by injecting saline into the anterior chamber and transiently applying an intraocular pressure of approximately 100 mmHg. It is used forevaluating drugs intended to treat or prevent retinopathy.
No case studies are currently listed on the official website.
For over 40 years, Drug Safety Testing Center Co., Ltd. has been providing reliable, high-quality non-clinical testing services for pharmaceuticals, quasi-drugs, and veterinary products.
| Address | 1-31-8 Takadanobaba, Shinjuku-ku, Tokyo |
|---|---|
| Tel | 0493-54-3239 |
| Website | https://www.dstc.jp/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.